AI in Bioinformatics and Biomedical Computation for Neurodegenerative Disorder Study

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Bioinformatics and Systems Biology".

Deadline for manuscript submissions: closed (25 March 2024) | Viewed by 3392

Special Issue Editor


E-Mail Website
Guest Editor
Intelligent Systems Research Centre, School of Computing, Engineering & Intelligent Systems, Ulster University, Northern Ireland BT48 7JL, UK
Interests: data analytics; predictive modelling; novelty detection; data science in healthcare domain; computing in Alzheimer’s disease

Special Issue Information

Dear Colleagues,

Dementia is a neurodegenerative disorder and the 7th leading cause of death worldwide. The risk of developing dementia may vary depending on the following factors: biological ageing, apolipoprotein E genotype, hypertension, diabetes, smoking, alcohol, depression and so on. It is a syndrome caused by a number of diseases, which over time destroy nerve cells and damage the brain, leading to cognitive dysfunction. The illness worsens over time and currently cannot be cured by regular treatment, while early diagnosis and prognosis bring individuals and their carers some benefits, e.g., by allowing patients to make informed decisions and plan ahead, seek support on financial and legal matters, and receive practical guidance as they face new challenges. Effectively utilizing AI techniques can reliably and timely predict the severity of individuals suffering from mild cognitive impairment and dementia.

This Special Issue aims to showcase the interdisciplinary research across computing, biology, medicine, and bioinformatics based on non-imaging and imaging data for neurodegeneration prediction, finding quantitative key significant factors of the disease that may include, but are not limited to, molecular mechanisms with biological and medical implications.

Please kindly note that the journal focuses on the structures and functions of bioactive as well as biogenic substances, molecular mechanisms with biological and medical implications, and biomaterials and their applications. Pure clinical research will not be considered.

Original research articles and reviews are welcome. We look forward to receiving your contributions.

Dr. Xuemei Ding
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegenerative disease and neuroimaging
  • clinical decision support systems for translational application
  • AI-driven bioinformatics and computational biomedicine
  • explainable analytics and data visualization for diagnosis and prognosis
  • data mining, analytics, and predictive modelling
  • biological factors for neurodegenerative disorder

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 913 KiB  
Review
The Potential of a Stratified Approach to Drug Repurposing in Alzheimer’s Disease
by Chloe Anderson, Magda Bucholc, Paula L. McClean and Shu-Dong Zhang
Biomolecules 2024, 14(1), 11; https://doi.org/10.3390/biom14010011 - 21 Dec 2023
Cited by 3 | Viewed by 2999
Abstract
Alzheimer’s disease (AD) is a complex neurodegenerative condition that is characterized by the build-up of amyloid-beta plaques and neurofibrillary tangles. While multiple theories explaining the aetiology of the disease have been suggested, the underlying cause of the disease is still unknown. Despite this, [...] Read more.
Alzheimer’s disease (AD) is a complex neurodegenerative condition that is characterized by the build-up of amyloid-beta plaques and neurofibrillary tangles. While multiple theories explaining the aetiology of the disease have been suggested, the underlying cause of the disease is still unknown. Despite this, several modifiable and non-modifiable factors that increase the risk of developing AD have been identified. To date, only eight AD drugs have ever gained regulatory approval, including six symptomatic and two disease-modifying drugs. However, not all are available in all countries and high costs associated with new disease-modifying biologics prevent large proportions of the patient population from accessing them. With the current patient population expected to triple by 2050, it is imperative that new, effective, and affordable drugs become available to patients. Traditional drug development strategies have a 99% failure rate in AD, which is far higher than in other disease areas. Even when a drug does reach the market, additional barriers such as high cost and lack of accessibility prevent patients from benefiting from them. In this review, we discuss how a stratified medicine drug repurposing approach may address some of the limitations and barriers that traditional strategies face in relation to drug development in AD. We believe that novel, stratified drug repurposing studies may expedite the discovery of alternative, effective, and more affordable treatment options for a rapidly expanding patient population in comparison with traditional drug development methods. Full article
Show Figures

Figure 1

Back to TopTop